Transaortic Aortic Valve Implantation in 100 Patients: Follow-up to 3 Years. Issue 2 (March 2016)

• Record Type: Journal Article
• Authors: Cocchieri, Riccardo; Koh, Ezra Y.; Wollersheim, Laurens W.; Meregalli, Paola G.; Bardai, Abdenasser; Bouma, Berto J.; De Mol, Bas A.
• Is Part Of: Innovations. Volume 11:Issue 2(2016)
• Page Start: 106
• Page End: 111
• Publication Date: 2016-03
• Subjects: Transcatheter aortic valve implantation -- Aortic valve stenosis -- Transaortic approach; Cardiovascular system -- Surgery -- Periodicals; Heart -- Surgery -- Periodicals; Blood-vessels -- Surgery -- Periodicals; Chest -- Surgery -- Periodicals; Thoracic Surgical Procedures -- methods -- Periodicals; Vascular Surgical Procedures -- methods -- Periodicals; Thorax -- Chirurgie -- Méthodologie -- Périodiques; Vaisseaux sanguins -- Chirurgie -- Méthodologie -- Périodiques; Blood-vessels -- Surgery; Chest -- Surgery; Periodicals; 617.41
• DOI: 10.1177/155698451601100205
• Languages: English
• ISSNs: 1556-9845

Abstract

Objective: Transaortic aortic valve implantation (TAo-AVI) through the ascending aorta is a novel technique and is used as an alternative in patients with poor femoral access. Although early results have been promising, no midterm data have been published yet. To determine whether this approach is an acceptable treatment option, we analyzed the first 100 cases performed at our institution with a follow-up to 3 years. Methods: Between July 2011 and January 2015, a total of 100 patients with high-risk or inoperable aortic valve stenosis were treated with TAo-AVI. Preoperative patient data were collected and analyzed retrospectively. All surviving patients were seen for clinical and echocardiographic examination for follow-up. Results: Median follow-up was 15 months. Device success was accomplished in 94 patients (94%). There were no access site complications. The 30-day mortality rate was 9%. Stroke occurred in a total of six patients (6%). Survival at 1-, 2-, and 3 years was 75%, 62%, and 58%, respectively. Conclusions: Our results show that TAo-AVI is a promising alternative to transapical implantation for treating severe inoperable aortic valve stenosis.